John Phillip Doweiko, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Serum Albumin | 5 | 1994 | 673 | 0.390 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2004 | 79 | 0.270 |
Why?
|
| Vestibulocochlear Nerve Diseases | 1 | 2004 | 33 | 0.230 |
Why?
|
| Syphilis | 1 | 2004 | 243 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2004 | 1377 | 0.140 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 2 | 2010 | 138 | 0.130 |
Why?
|
| Thiazolidinediones | 2 | 2010 | 460 | 0.120 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 1422 | 0.120 |
Why?
|
| Anus Neoplasms | 2 | 2010 | 329 | 0.110 |
Why?
|
| Anus Diseases | 2 | 2010 | 55 | 0.100 |
Why?
|
| Subcutaneous Emphysema | 1 | 1992 | 15 | 0.100 |
Why?
|
| Leptin | 2 | 2010 | 1591 | 0.100 |
Why?
|
| HIV Infections | 6 | 2004 | 17275 | 0.100 |
Why?
|
| Platelet Aggregation | 1 | 1994 | 773 | 0.090 |
Why?
|
| Urinary Catheterization | 1 | 1992 | 198 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2010 | 1895 | 0.090 |
Why?
|
| Condylomata Acuminata | 1 | 2010 | 75 | 0.090 |
Why?
|
| Homosexuality, Male | 3 | 2010 | 1329 | 0.090 |
Why?
|
| Erythropoietin | 2 | 1991 | 719 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 1993 | 496 | 0.080 |
Why?
|
| Shock | 1 | 1991 | 314 | 0.080 |
Why?
|
| Postprandial Period | 1 | 2010 | 314 | 0.080 |
Why?
|
| Anemia | 3 | 1993 | 1504 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2008 | 2197 | 0.070 |
Why?
|
| HIV Seropositivity | 3 | 2010 | 960 | 0.060 |
Why?
|
| Fenofibrate | 1 | 2005 | 87 | 0.060 |
Why?
|
| Trazodone | 1 | 1984 | 68 | 0.060 |
Why?
|
| Complement Activation | 1 | 2004 | 446 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 1991 | 1090 | 0.050 |
Why?
|
| HIV-1 | 2 | 2010 | 6850 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 1927 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2004 | 914 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2010 | 6346 | 0.040 |
Why?
|
| Hypoglycemic Agents | 2 | 2010 | 3069 | 0.040 |
Why?
|
| Vitamin E | 1 | 2003 | 870 | 0.040 |
Why?
|
| Insulin Resistance | 2 | 2010 | 3941 | 0.040 |
Why?
|
| Immunotoxins | 1 | 1998 | 175 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 1612 | 0.040 |
Why?
|
| Otitis | 1 | 1997 | 21 | 0.040 |
Why?
|
| Protozoan Infections | 1 | 1997 | 39 | 0.040 |
Why?
|
| Parenteral Nutrition, Home Total | 1 | 1996 | 9 | 0.030 |
Why?
|
| Cushing Syndrome | 1 | 1998 | 241 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 1998 | 432 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 288 | 0.030 |
Why?
|
| Thrombocytopenia | 2 | 1993 | 1171 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 1984 | 1786 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 4023 | 0.030 |
Why?
|
| Piperazines | 1 | 1984 | 2511 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 662 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 1994 | 422 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1993 | 98 | 0.030 |
Why?
|
| Agranulocytosis | 1 | 1993 | 99 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 1993 | 32 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 1994 | 427 | 0.030 |
Why?
|
| Lung | 1 | 1991 | 9985 | 0.030 |
Why?
|
| Blood Component Transfusion | 1 | 1993 | 141 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 2008 | 3299 | 0.030 |
Why?
|
| Humans | 25 | 2010 | 758406 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 1984 | 3727 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 1996 | 526 | 0.020 |
Why?
|
| Buffers | 1 | 1991 | 144 | 0.020 |
Why?
|
| Epinephrine | 1 | 1994 | 790 | 0.020 |
Why?
|
| Colloids | 1 | 1991 | 122 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 1991 | 86 | 0.020 |
Why?
|
| Nutrition Disorders | 1 | 1991 | 205 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1993 | 349 | 0.020 |
Why?
|
| Cryptococcosis | 1 | 1990 | 104 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 6293 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1991 | 1141 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2010 | 211 | 0.020 |
Why?
|
| Male | 14 | 2010 | 358747 | 0.020 |
Why?
|
| Ascites | 1 | 1991 | 338 | 0.020 |
Why?
|
| Body Fluids | 1 | 1991 | 319 | 0.020 |
Why?
|
| Adult | 10 | 2010 | 219935 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 1991 | 249 | 0.020 |
Why?
|
| Hemostasis | 1 | 1991 | 466 | 0.020 |
Why?
|
| Cytokines | 2 | 1993 | 7338 | 0.020 |
Why?
|
| Sinusitis | 1 | 1997 | 990 | 0.020 |
Why?
|
| Neutropenia | 1 | 1993 | 884 | 0.020 |
Why?
|
| Warfarin | 1 | 1996 | 1482 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 9160 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 206 | 0.020 |
Why?
|
| Alphapapillomavirus | 1 | 2010 | 219 | 0.020 |
Why?
|
| Anti-HIV Agents | 2 | 2005 | 4504 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1991 | 788 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1991 | 1866 | 0.020 |
Why?
|
| Exercise | 1 | 2003 | 5788 | 0.020 |
Why?
|
| HIV | 1 | 1993 | 1581 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 1991 | 2457 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 1992 | 1166 | 0.020 |
Why?
|
| Adiponectin | 1 | 2010 | 1114 | 0.010 |
Why?
|
| Placebos | 1 | 2008 | 1661 | 0.010 |
Why?
|
| Monocytes | 1 | 1993 | 2570 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1993 | 2047 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1991 | 1398 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1993 | 2909 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1991 | 1185 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 2048 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1991 | 1296 | 0.010 |
Why?
|
| Neoplasms | 1 | 1991 | 22032 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 3617 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 6520 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1991 | 1392 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1991 | 1910 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1991 | 1930 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1991 | 2083 | 0.010 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 609 | 0.010 |
Why?
|
| Wound Healing | 1 | 1991 | 2783 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 1147 | 0.010 |
Why?
|
| Ricin | 1 | 1998 | 70 | 0.010 |
Why?
|
| Protein Binding | 1 | 1991 | 9311 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 772 | 0.010 |
Why?
|
| Microsporida | 1 | 1997 | 6 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 11709 | 0.010 |
Why?
|
| Bleomycin | 1 | 1998 | 495 | 0.010 |
Why?
|
| Amebiasis | 1 | 1997 | 33 | 0.010 |
Why?
|
| Microsporidiosis | 1 | 1997 | 23 | 0.010 |
Why?
|
| Albendazole | 1 | 1997 | 50 | 0.010 |
Why?
|
| Animals | 5 | 1997 | 167768 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 8553 | 0.010 |
Why?
|
| Cryptosporidiosis | 1 | 1997 | 53 | 0.010 |
Why?
|
| Antiprotozoal Agents | 1 | 1997 | 94 | 0.010 |
Why?
|
| Anthelmintics | 1 | 1997 | 82 | 0.010 |
Why?
|
| Antibiotics, Antitubercular | 1 | 1997 | 99 | 0.010 |
Why?
|
| Leucovorin | 1 | 1998 | 641 | 0.010 |
Why?
|
| Eating | 1 | 2003 | 1536 | 0.010 |
Why?
|
| Vincristine | 1 | 1998 | 1038 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1994 | 5816 | 0.010 |
Why?
|
| Insulin | 1 | 2010 | 6578 | 0.010 |
Why?
|
| Middle Aged | 5 | 2010 | 219568 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1991 | 6548 | 0.010 |
Why?
|
| Antioxidants | 1 | 2003 | 1662 | 0.010 |
Why?
|
| Liver | 1 | 1991 | 7502 | 0.010 |
Why?
|
| Ear, Middle | 1 | 1997 | 338 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2008 | 25956 | 0.010 |
Why?
|
| Body Composition | 1 | 2003 | 2416 | 0.010 |
Why?
|
| Nose | 1 | 1997 | 519 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2010 | 12876 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 2218 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1991 | 11892 | 0.010 |
Why?
|
| Adolescent | 2 | 2010 | 87892 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 1997 | 749 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 6768 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1998 | 2209 | 0.010 |
Why?
|
| Methotrexate | 1 | 1998 | 1719 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 1927 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 12262 | 0.010 |
Why?
|
| Cobalt | 1 | 1991 | 154 | 0.010 |
Why?
|
| Prognosis | 1 | 1991 | 29557 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1998 | 1802 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2003 | 3387 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 1997 | 981 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1990 | 121 | 0.010 |
Why?
|
| Weight Gain | 1 | 1998 | 2346 | 0.000 |
Why?
|
| Blood Pressure | 1 | 2003 | 8451 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2010 | 41256 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 8530 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 2010 | 80168 | 0.000 |
Why?
|
| Female | 5 | 2008 | 390323 | 0.000 |
Why?
|
| Diet | 1 | 2003 | 8005 | 0.000 |
Why?
|
| Recurrence | 1 | 1997 | 8426 | 0.000 |
Why?
|
| Aged | 2 | 2010 | 168218 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1996 | 3400 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 58808 | 0.000 |
Why?
|
| Transfection | 1 | 1991 | 5779 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 7403 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 21272 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 7590 | 0.000 |
Why?
|
| Cell Line | 1 | 1991 | 15591 | 0.000 |
Why?
|
| Risk Factors | 1 | 1996 | 73809 | 0.000 |
Why?
|